Do you want to read an article? Please log in or register.
Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial
Related content
COMMENTED
COPD
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
doi: 10.1016/S2213-
COPD
Care in Chronic Obstructive Lung Disease (CAROL): a randomised trial in general practice
Eur Respir J.
Markun S, Rosemann T, Dalla-Lana K, Steurer-Stey C
doi: 10.1183/13993003.
AsthmaCOPD
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Lancet Respir Med.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M
doi: 10.1016/
RECOMMENDED
COPD
Chronic Obstructive Pulmonary Disease in the Intensive Care Unit: Antibiotic Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Semin Respir Crit Care Med.
Gupta N, Haley R, Gupta A, Sethi S
doi: 10.1055/s-0040-1708837.
COMMENTED
COPD
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respir Med.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C
doi: 10.1016/S2213-2600
COMMENTED
COPD
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev.
Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA
doi: 10.1002/14651858.
RECOMMENDED
Pulmonary Fibrosis
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J, Scotton CJ
doi: 10.1016/S2213-2600(20)30364-7.Visit the original publication at ncbi.nlm.nih.gov
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Lancet.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators
doi: 10.1016/
COPD
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
Lancet.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D
doi: 10.1016/S0140-6736